In a phase I clinical trial at Nankai University, China by Jin et al., ten r/r AML patients treated with anti-CLL-1 CAR T-cells demonstrated a 70% complete remission or complete remission with incomplete hematological recovery (CR/CRi) (17). This evidence concerns the gene CLEC12A and acute myeloid leukemia.